Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Nature|March 7, 2014
doublesex is a mimicry supergeneK Kunte, W Zhang, A Tenger-Trolander, et al.
British Journal of Cancer|August 5, 2004
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancerS A Hussain, D D Stocken, P Riley, et al.
British Journal of Cancer|July 25, 2013
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United KingdomD H Palmer, S A Hussain, A J Smith, et al.
Cell Death and Differentiation|February 23, 2002
Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cellsA E Milner, D H Palmer, E A Hodgkin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2017
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic scoreJ Edeline, J-F Blanc, B Campillo-Gimenez, et al.
The British Journal of Surgery|January 29, 2015
Evaluation of a novel tissue stabilization gel to facilitate clinical sampling for translational research in surgical trialsP A Sutton, R P Jones, F Morrison, et al.
British Journal of Cancer|March 16, 2013
Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicityS Vinjamuri, T M Gilbert, M Banks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2013
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancerL Kadalayil, R Benini, L Pallan, et al.
The British Journal of Surgery|February 12, 2016
Randomized clinical trial of prehabilitation before planned liver resectionD F J Dunne, S Jack, R P Jones, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancerT Meyer, M E Caplin, D H Palmer, et al.
Pageof 4